
Ilies Benotmane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1970701/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA - Journal of the American Medical Association, 2021, 326, 1063.	7.4	300
2	Is COVID-19 infection more severe in kidney transplant recipients?. American Journal of Transplantation, 2021, 21, 1295-1303.	4.7	190
3	Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney International, 2021, 99, 1498-1500.	5.2	163
4	Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney International, 2021, 99, 1487-1489.	5.2	126
5	Cytokine release syndromeâ€associated encephalopathy in patients with COVIDâ€19. European Journal of Neurology, 2021, 28, 248-258.	3.3	114
6	Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. Annals of Internal Medicine, 2022, 175, 455-456.	3.9	98
7	In-depth virological assessment of kidney transplant recipients with COVID-19. American Journal of Transplantation, 2020, 20, 3162-3172.	4.7	68
8	Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. Kidney International, 2021, 100, 466-468.	5.2	60
9	First case of COVID-19 in a kidney transplant recipient treated with belatacept. American Journal of Transplantation, 2020, 20, 1944-1946.	4.7	55
10	Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Science Translational Medicine, 2022, 14, eabl6141.	12.4	52
11	Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. American Journal of Transplantation, 2022, 22, 2675-2681.	4.7	48
12	Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. Journal of Infectious Diseases, 2021, 223, 600-609.	4.0	47
13	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. Kidney International, 2022, 101, 1073-1076.	5.2	44
14	Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients. Transplantation, 2021, 105, 158-169.	1.0	34
15	Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant. Kidney International, 2022, 102, 442-444.	5.2	34
16	Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19. American Journal of Transplantation, 2021, 21, 2871-2875.	4.7	33
17	Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115181.	1.8	29
18	Is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present intraperitoneally in patients with coronavirus disease 2019 (COVID-19) infection undergoing emergency operations?. Surgery, 2020, 168, 220-221.	1.9	25

ILIES BENOTMANE

#	Article	IF	CITATIONS
19	A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients. Kidney International, 2022, 101, 825-826.	5.2	25
20	Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients—Results from a proof-of-concept study. American Journal of Transplantation, 2021, 21, 329-337.	4.7	24
21	SARS-CoV-2 viral dynamics in immunocompromised patients. American Journal of Transplantation, 2021, 21, 1667-1669.	4.7	23
22	Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	20
23	Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. American Journal of Transplantation, 2021, 21, 3808-3810.	4.7	20
24	Persistence of SARS-CoV-2 antibodies in kidney transplant recipients. American Journal of Transplantation, 2021, 21, 2307-2310.	4.7	20
25	Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab. Kidney International, 2020, 98, 508-509.	5.2	17
26	Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation. Kidney International Reports, 2022, 7, 983-992.	0.8	12
27	Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia. Journal of Clinical Virology, 2022, 148, 105120.	3.1	7
28	Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study. Journal of Personalized Medicine, 2022, 12, 1107.	2.5	5
29	COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report. Journal of Nephrology, 2021, 34, 1045-1048.	2.0	4
30	Letter to the Editor concerning "Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy― American Journal of Transplantation, 2019, 19, 3438-3439.	4.7	1
31	Le BK virus en greffe rénale. Revue Francophone Des Laboratoires, 2019, 2019, 44-52.	0.0	Ο
32	SARS-Cov-2 Seroprevalence in a French Kidney Transplant Center Located Within a "High Risk―Zone. Transplantation, 2021, Publish Ahead of Print, 2165-2169.	1.0	0